Creative Medical Technology Holdings Inc (OTCMKTS:CELZ) has exploded more than 200% over the last 30 days and has volatility has followed. Furthermore, CELZ saw 90M shares trade hands yesterday, adding weight to a potential reversal of fortunes for the stem cell company.
The key driver points to increased visibility for CELZ’s erectile dysfunction platform at the American Urological Association. The company will demonstrate their technology to a large and prestigious crowd that could carry the word back to decision makers on CELZ’s tech, according to the company. “Since beginning commercialization of our patented and tested CaverStemTM procedure in November 2017, we have received positive responses from the urology community in the limited cities marketed. We anticipate the introduction of our technology to the attendees of the largest annual urology conference, to promote nationwide interest in CaverStemTM,” said Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings Inc (OTCMKTS:CELZ) bills itself as a company that is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility and related issues. It holds a patent for its erectile dysfunction (“ED”) treatment and was granted a license by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, a non-profit biomedical research and education institute (“LABIOMED”), for the infertility treatment.
It has also filed a patent application focused on physical manifestations of female sexual arousal disorder, as an extension of the work with stem cell therapies for ED. Following testing of its ED treatment, Creative Medical intends to market treatment kits to physicians for use with their patients suffering from ED. During first quarter 2016, it commenced a 15-month clinical trial study being conducted at UCLA by LABIOMED on the efficacy and safety of the ED treatment.
The study involves testing on 40 subjects. Following further testing, Creative Medical also intends to market licensed products under its infertility technology license and the female sexual dysfunction patent application.
Find out when $CELZ stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
In case readers are not aware, the Caverstem procedure involves the use of patient’s bone marrow-derived stem cell to treat drug-resistant erectile dysfunction.
CELZ is currently offering the procedure to selected urologists across the U.S. Since the commercialization of the procedure began late last year, the company says it has received positive feedback from medical doctors in the Southwest United States.
CELZ is currently recruiting doctors in Los Angeles, Orange County, San Diego and Las Vegas as part of an effort that seeks to broaden the procedure’s awareness.
In addition, CELZ announced that $250,000 in debt from early round lenders have been extinguished. The company stated this in the press: “As with many small companies, we took on debt in order to advance our technologies and continue towards our goal of commercialization and cash flow.”
These two combined pieces of news have boosted the company in recent trading and brought some confidence back to this stock.
Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) has a market cap of $2.74M and a float of 63.87M. CELZ has a long way to go to climb out of its 52-week whole and their needs to be more than speculation for investors to push this above significant support levels. We will be updating readers as soon as possible as this story colors out over the next few days. Sign-up for continuing coverage on shares of $CELZ stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick